Quantcast

Latest zolpidem Stories

2009-05-20 13:27:06

Cognitive behavior therapy and the medication zolpidem taken for six weeks improved sleep in those with persistent insomnia, Canadian researchers found. Charles M. Morin of the Universite Laval in Quebec City and colleagues evaluated the short- and long-term effects of cognitive behavior therapy singly and combined with the medication zolpidem, for persistent insomnia, and compared treatment strategies to optimize long-term outcomes. The trial included 160 adults, who were randomized to...

2009-05-20 06:59:28

People suffering from insomnia appear to benefit from cognitive behavior therapy (CBT). A recent study found CBT used alone or with the medication zolpidem (Ambien) led to significant improvements in the amount of time it took to fall asleep, the amount of times a person woke up during the night, and how well a person slept during the initial therapy. Researchers at the University Laval in Quebec, Canada, compared the short-term and long-term effects of CBT combined with the zolpidem on...

fa1ba12e98af16b03725744acd26cf5d1
2009-01-16 06:55:00

Need the help of a pill to catch some zzz's? According to a new study you're not alone; the use of prescription sleep aids nearly tripled among young adults between 1998 and 2006."Insomnia, a condition traditionally associated with older adults, appears to be causing larger numbers of young adults to turn to prescription sleep aids, and to depend on them for longer periods of time," said William Marder, senior vice president and general manager for the healthcare business of Thomson Reuters,...

2008-12-16 08:00:00

FDA to review Intermezzo(R) (zolpidem tartrate sublingual lozenge) as the first sleep aid specifically designed for the treatment of middle-of-the-night awakenings PT. RICHMOND, Calif., Dec. 16 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for Intermezzo(R) (zolpidem tartrate sublingual lozenge) has been...

2008-12-01 08:00:00

PT. RICHMOND, Calif., Dec. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to participate at the RBC Capital Markets 2008 Healthcare Conference in New York City on a panel entitled "Delivering Novel Drug Solutions: The Future of Drug Delivery." This presentation is scheduled to take place on Thursday, December 11, 2008 at 1:30 PM Eastern...

2008-10-22 09:00:42

PT. RICHMOND, Calif., Oct. 22 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that a Phase 3 study evaluating the safety and efficacy of its lead product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge), has been published in the September 2008 issue of SLEEP, a publication of the Associated Professional Sleep Societies. Intermezzo(R) is a low dose, buffered, sublingual formulation of zolpidem intended to be...

2008-10-08 09:00:50

PT. RICHMOND, Calif., Oct. 8 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Thomas P. Soloway, Senior Vice President and Chief Financial Officer, is scheduled to present at the Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City on Monday, October 13, 2008 at 9:30 AM Eastern Time. An audio webcast of the presentation will be available at http://www.wsw.com/webcast/nblr2/transcept/ and on the...

2008-09-19 09:00:40

NovaDel Pharma, a specialty pharmaceutical company, has announced that the FDA has requested an extension of up to three months on the Prescription Drug User Fee Act deadline in order to complete the review of the company's Zolpimist oral spray for the short-term treatment of insomnia. Based on the original Prescription Drug User Fee Act (PDUFA) date for Zolpimist, the FDA will reply on or before December 19, 2008. NovaDel submitted its Zolpimist application using the FDA's 505(b)(2)...

2008-09-18 18:00:19

NovaDel Pharma Inc. (AMEX: NVD) today announced that the U.S. Food and Drug Administration (FDA) has requested an extension of up to 3 months on the Prescription Drug User Fee Act (PDUFA) deadline in order to complete the review of the Company's Zolpimist (zolpidem tartrate) Oral Spray for the short-term treatment of insomnia. Based on the original PDUFA date for Zolpimist, the FDA will reply on or before December 19, 2008. "We believe we have submitted a high quality 505(b)(2) application...

2008-09-02 03:00:33

Novacea, Inc. (NASDAQ: NOVC) and Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that they have entered into a definitive merger agreement under which Novacea will merge with Transcept in an all-stock transaction. Under the terms of the merger agreement, Novacea will issue new shares of its common stock to Transcept stockholders based on an exchange ratio to be determined prior to the closing of the transaction. Under the exchange ratio...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin